Biomonitor III cardiac monitor is launched in Europe with CE Mark

BIOTRONIK announced the market release of its new injectable cardiac monitor (ICM), Biomonitor III, following approval in the CE region. The novel device is designed to help patients with irregular heart rhythms by documenting suspected arrhythmia or unexplained syncope with increased clarity.

As the most common type of arrhythmia, 33.5 million patients worldwide suffer from atrial fibrillation (AF). It is associated with a five-fold increase in risk of stroke, a three-fold increase in incidence of congestive heart failure, and higher mortality. Aiming to improve the accuracy of arrhythmia detection and diagnosis, BIOTRONIK’s new ICM offers increased signal quality.

BioMonitor III is designed to be injected under the skin, where it can reside for weeks while continuously monitoring and recording the patient’s electrical heart signals. This can help detect cardiac arrhythmias and unexplained syncopes (loss of consciousness). Atrial fibrillation will be the main diagnostic target of the Biomonitor III. The new monitor can significantly increase signal amplitudes and the visibility of p-waves compared with the previous generation of the device, helping cardiologists to better spot arrhythmias.